Literature DB >> 33587109

Experimental Designs to Optimize Treatments for Individuals: Personalized N-of-1 Trials.

Karina W Davidson1,2, Michael Silverstein3, Ken Cheung4, Rocco A Paluch5, Leonard H Epstein5.   

Abstract

Conventional randomized clinical trials (RCTs) compare treatment effectiveness to provide support for evidence-based treatments that can be generalized to the average patient. However, the information obtained from RCTs may not always be useful for selecting the best treatment for individual patients. This article presents a complementary approach to identifying optimized treatments using experimental designs that focus on individuals. Personalized, or N-of-1, designs provide both a comparative analysis of treatments and a functional analysis demonstrating that changes in patient symptoms are likely because of the treatment implemented. This approach contributes to the zeitgeist of personalized medicine and provides clinicians with a paradigm for investigating optimal treatments for rare diseases for which RCTs are not always feasible, identifying personally effective treatments for patients with comorbidities who have historically been excluded from most RCTs, handling clinical situations in which patients respond idiosyncratically (either positively or negatively) to treatment, and shortening the time lag between identification and implementation of an evidence-based treatment. These designs merge experimental analysis of behavior methods used for decades in psychology with new methodological and statistical advances to assess significance levels of changes in individual patients, and they can be generalized to larger populations for meta-analytic purposes. This article presents a case for why these models are needed, an overview of how to apply personalized designs for different types of clinical scenarios, and a brief discussion of challenges associated with interpretation and implementation of personalized designs. The goal is to empower pediatricians to take personalized trial designs into clinical practice to identify optimal treatments for their patients.

Entities:  

Mesh:

Year:  2021        PMID: 33587109      PMCID: PMC8351788          DOI: 10.1001/jamapediatrics.2020.5801

Source DB:  PubMed          Journal:  JAMA Pediatr        ISSN: 2168-6203            Impact factor:   16.193


  14 in total

1.  Do n-of-1 trials really tailor treatment?

Authors:  Andrew Jull; Derrick Bennett
Journal:  Lancet       Date:  2005 Jun 11-17       Impact factor: 79.321

2.  The randomized registry trial--the next disruptive technology in clinical research?

Authors:  Michael S Lauer; Ralph B D'Agostino
Journal:  N Engl J Med       Date:  2013-08-31       Impact factor: 91.245

3.  A gate-keeping test for selecting adaptive interventions under general designs of sequential multiple assignment randomized trials.

Authors:  Xiaobo Zhong; Bin Cheng; Min Qian; Ying Kuen Cheung
Journal:  Contemp Clin Trials       Date:  2019-08-27       Impact factor: 2.226

4.  Increasing the Precision of Hypertension Treatment Through Personalized Trials: a Pilot Study.

Authors:  Ian M Kronish; Ying Kuen Cheung; Daichi Shimbo; Jacob Julian; Benjamin Gallagher; Faith Parsons; Karina W Davidson
Journal:  J Gen Intern Med       Date:  2019-03-11       Impact factor: 5.128

5.  The impact of high-risk patients on the results of clinical trials.

Authors:  J P Ioannidis; J Lau
Journal:  J Clin Epidemiol       Date:  1997-10       Impact factor: 6.437

6.  Determining optimal therapy--randomized trials in individual patients.

Authors:  G Guyatt; D Sackett; D W Taylor; J Chong; R Roberts; S Pugsley
Journal:  N Engl J Med       Date:  1986-04-03       Impact factor: 91.245

7.  What ever happened to N-of-1 trials? Insiders' perspectives and a look to the future.

Authors:  Richard L Kravitz; Naihua Duan; Edmund J Niedzinski; M Cameron Hay; Saskia K Subramanian; Thomas S Weisner
Journal:  Milbank Q       Date:  2008-12       Impact factor: 4.911

8.  Single-patient randomised clinical trial. Use in determining optimum treatment for patient with inflammation of Kock continent ileostomy reservoir.

Authors:  R S McLeod; D W Taylor; Z Cohen; J B Cullen
Journal:  Lancet       Date:  1986-03-29       Impact factor: 79.321

9.  Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal.

Authors:  David M Kent; Peter M Rothwell; John P A Ioannidis; Doug G Altman; Rodney A Hayward
Journal:  Trials       Date:  2010-08-12       Impact factor: 2.279

10.  Clinical Usefulness of Bright White Light Therapy for Depressive Symptoms in Cancer Survivors: Results from a Series of Personalized (N-of-1) Trials.

Authors:  Ian M Kronish; Ying Kuen Cheung; Jacob Julian; Faith Parsons; Jenny Lee; Sunmoo Yoon; Heidis Valdimarsdottir; Paige Green; Jerry Suls; Dawn L Hershman; Karina W Davidson
Journal:  Healthcare (Basel)       Date:  2019-12-30
View more
  5 in total

1.  Valuing the Diversity of Research Methods to Advance Nutrition Science.

Authors:  Richard D Mattes; Sylvia B Rowe; Sarah D Ohlhorst; Andrew W Brown; Daniel J Hoffman; DeAnn J Liska; Edith J M Feskens; Jaapna Dhillon; Katherine L Tucker; Leonard H Epstein; Lynnette M Neufeld; Michael Kelley; Naomi K Fukagawa; Roger A Sunde; Steven H Zeisel; Anthony J Basile; Laura E Borth; Emahlea Jackson
Journal:  Adv Nutr       Date:  2022-08-01       Impact factor: 11.567

2.  First Steps toward Personalized Therapies for ABCA3 Deficiency.

Authors:  Jennifer A Wambach; Lawrence M Nogee; F Sessions Cole
Journal:  Am J Respir Cell Mol Biol       Date:  2022-04       Impact factor: 7.748

3.  Breaking new frontiers: Assessment and re-evaluation of clinical trial design for nutraceuticals.

Authors:  Malkanthi Evans; Erin D Lewis; Joseph M Antony; David C Crowley; Najla Guthrie; Jeffrey B Blumberg
Journal:  Front Nutr       Date:  2022-09-23

4.  Perspective: Leveraging the Gut Microbiota to Predict Personalized Responses to Dietary, Prebiotic, and Probiotic Interventions.

Authors:  Sean M Gibbons; Thomas Gurry; Johanna W Lampe; Anirikh Chakrabarti; Veerle Dam; Amandine Everard; Almudena Goas; Gabriele Gross; Michiel Kleerebezem; Jonathan Lane; Johanna Maukonen; Ana Lucia Barretto Penna; Bruno Pot; Ana M Valdes; Gemma Walton; Adrienne Weiss; Yoghatama Cindya Zanzer; Naomi V Venlet; Michela Miani
Journal:  Adv Nutr       Date:  2022-10-02       Impact factor: 11.567

5.  Imagine to Remember: An Episodic Future Thinking Intervention to Improve Medication Adherence in Patients with Type 2 Diabetes.

Authors:  Leonard H Epstein; Tatiana Jimenez-Knight; Anna M Honan; Rocco A Paluch; Warren K Bickel
Journal:  Patient Prefer Adherence       Date:  2022-01-13       Impact factor: 2.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.